文献速递区域麻醉与超声疼痛医学

脂质体布比卡因不减少膝关节置换术后住院阿片处方及相关并发症:数据库分析

Liposomal Bupivacaine Does Not Reduce Inpatient Opioid Prescription or Related Complications after Knee Arthroplasty: A Database Analysis.
PubMed 文献 · Anesthesiology · 2018-01-01

基于Premier医疗数据库2013至2016年88,830例接受外周神经阻滞的全膝关节置换术,脂质体布比卡因使用率21.2%(n=18,817)。多水平多变量回归显示,其使用与住院阿片处方、住院时长、住院费用及阿片相关并发症均无临床相关改善。

要点

  • 脂质体布比卡因使用率21.2%,与住院阿片处方无临床意义降低相关。
  • 住院时长组中位3天,校正效应-8.8%,未达预设-15%临床重要阈值。
  • 脂质体布比卡因未降低阿片相关并发症的几率,对住院费用无影响。

核心结论

  • 在现代疼痛管理(含外周神经阻滞)下,脂质体布比卡因与住院阿片处方、资源利用及阿片相关并发症的临床相关改善无关。

研究设计与样本

  • 回顾性数据库分析,纳入Premier Healthcare Database 2013至2016年88,830例接受外周神经阻滞的全膝关节置换术。
  • 采用多水平多变量回归分析脂质体布比卡因使用与结局的关联,预设结局相对变化-15%为临床重要。

主要发现

  • 脂质体布比卡因总体使用率为21.2%(n=18,817)。
  • 脂质体布比卡因使用未与阿片相关并发症几率下降相关。

关键数值与推荐

  • 临床重要性阈值:结局相对变化-15%。

临床怎么用

  • 在已采用外周神经阻滞等现代疼痛管理方案的膝关节置换患者中,不应期待脂质体布比卡因带来临床相关的阿片节省或资源利用改善。

局限性

  • 为数据库分析,阿片处方从账单数据提取,可能存在编码与混杂偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

WHAT WE ALREADY KNOW ABOUT THIS TOPIC: WHAT THIS MANUSCRIPT TELLS US THAT IS NEW: BACKGROUND:: Although some trials suggest benefits of liposomal bupivacaine, data on real-world use and effectiveness is lacking. This study analyzed the impact of liposomal bupivacaine use (regardless of administration route) on inpatient opioid prescription, resource utilization, and opioid-related complications among patients undergoing total knee arthroplasties with a peripheral nerve block. It was hypothesized that liposomal bupivacaine has limited clinical influence on the studied outcomes. METHODS: The study included data on 88,830 total knee arthroplasties performed with a peripheral nerve block (Premier Healthcare Database 2013 to 2016). Multilevel multivariable regressions measured associations between use of liposomal bupivacaine and (1) inpatient opioid prescription (extracted from billing) and (2) length of stay, cost of hospitalization, as well as opioid-related complications. To reflect the difference between statistical and clinical significance, a relative change of -15% in outcomes was assumed to be clinically important. RESULTS: Overall, liposomal bupivacaine was used in 21.2% (n = 18,817) of patients that underwent a total knee arthroplasty with a peripheral nerve block. Liposomal bupivacaine use was not associated with a clinically meaningful reduction in inpatient opioid prescription (group median, 253 mg of oral morphine equivalents, adjusted effect -9.3% CI -11.1%, -7.5%; P < 0.0001) and length of stay (group median, 3 days, adjusted effect -8.8% CI -10.1%, -7.5%; P < 0.0001) with no effect on cost of hospitalization. Most importantly, liposomal bupivacaine use was not associated with decreased odds for opioid-related complications. CONCLUSIONS: Liposomal bupivacaine was not associated with a clinically relevant improvement in inpatient opioid prescription, resource utilization, or opioid-related complications in patients who received modern pain management including a peripheral nerve block.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Pichler L, Poeran J, Zubizarreta N, et al. Liposomal Bupivacaine Does Not Reduce Inpatient Opioid Prescription or Related Complications after Knee Arthroplasty: A Database Analysis. Anesthesiology. 2018. PMID: 29787389. doi:10.1097/ALN.0000000000002267

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。